EMAIL THIS PAGE TO A FRIEND

Acta diabetologica

Effects of long-term resveratrol-induced SIRT1 activation on insulin and apoptotic signalling in aged skeletal muscle.


PMID 25959421

Abstract

Activation of Foxo1 is known to promote apoptosis and disturbances to insulin signalling. However, their modulating roles in aged skeletal muscle are not clear. The present study tested the hypothesis that long-term (i.e. 8 month) resveratrol supplementation would improve physical traits including exercise capacity and basal voluntary activity of aged mice and modulate insulin/apoptotic signalling in aged skeletal muscle. This study also examined whether these resveratrol-associated alterations would involve orchestration of the SIRT1-Foxo1 signalling axis. Two-month-old SAMP8 mice were randomly assigned to young, aged and aged with resveratrol treatment (AR) groups. The AR mice were supplemented with 4.9 mg(-1) kg(-1) day(-1) resveratrol for 8 months. All animals were subject to endurance capacity test and voluntary motor behaviour assessment. The lateral gastrocnemius muscle tissues were harvested for further analyses. Long-term resveratrol treatment significantly alleviated the age-associated reductions in exercise capacity and voluntary motor behaviour. The protein content, but not the deacetylase activity of SIRT1 was increased with concomitant elevations of p300 acetylase and acetylation of Foxo1 in aged muscle. The aged muscle also manifested signs of impaired insulin signalling including attenuated phosphorylation of Akt, activity of pyruvate dehydrogenase and membrane trafficking of GLUT4 and elevated levels of phosphorylated IRS1 and iNOS and apoptotic activation measured as Bim, p53 and apoptotic DNA fragmentation. Intriguingly, all these age-related adverse changes were mitigated with the activation of SIRT1 deacetylase activity after long-term resveratrol treatment. These data suggest that modulation of the SIRT1-Foxo1 axis by long-term resveratrol treatment enhances physical traits and alleviates the unfavourable changes in insulin and apoptotic signalling in aged muscle.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA002725
Anti-DMD antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA023885
Anti-DMD antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1408565
Anti-DMD antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB4502012
Anti-INOS, C-Terminal antibody produced in rabbit, affinity isolated antibody
PRS4645
Anti-Nanos2 (ab1) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
PRS4647
Anti-Nanos2 (ab2) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB1300304
Anti-NANOS2 (C-term) antibody produced in rabbit, saturated ammonium sulfate (SAS) precipitated, buffered aqueous solution
SAB1408499
Anti-NANOS2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA014190
Anti-NANOS2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1402751
Monoclonal Anti-DMD antibody produced in mouse, clone 3A11, purified immunoglobulin, buffered aqueous solution
D8168
Monoclonal Anti-Dystrophin antibody produced in mouse, clone MANDYS8, ascites fluid
D8043
Monoclonal Anti-Dystrophin antibody produced in mouse, clone MANDRA1, ascites fluid